| NDC Number | Brand Name | Generic Name | Manufacturer | Dosage Form | DEA Sch. | Marketing Start Date |
|---|---|---|---|---|---|---|
| 0024-5908 | KEVZARA | sarilumab | Sanofi-Aventis U.S. LLC | INJECTION, SOLUTION | 2017-05-22 | |
| 0024-5910 | KEVZARA | sarilumab | Sanofi-Aventis U.S. LLC | INJECTION, SOLUTION | 2017-05-22 | |
| 0024-5920 | KEVZARA | sarilumab | Sanofi-Aventis U.S. LLC | INJECTION, SOLUTION | 2017-05-22 | |
| 0024-5922 | KEVZARA | sarilumab | Sanofi-Aventis U.S. LLC | INJECTION, SOLUTION | 2017-05-22 | |
| 50242-135 | ACTEMRA | tocilizumab | Genentech, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2010-01-08 | |
| 50242-136 | ACTEMRA | tocilizumab | Genentech, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2010-01-08 | |
| 50242-137 | ACTEMRA | tocilizumab | Genentech, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2010-01-08 | |
| 50242-138 | Actemra | tocilizumab | Genentech, Inc. | INJECTION, SOLUTION | 2013-10-21 | |
| 50242-143 | Actemra ACTPen | tocilizumab | Genentech, Inc. | INJECTION, SOLUTION | 2018-11-19 | |
| 64406-022 | Tofidence | TOCILIZUMAB | Biogen MA Inc. | INJECTION | 2024-05-01 | |
| 64406-023 | Tofidence | TOCILIZUMAB | Biogen MA Inc. | INJECTION | 2024-05-01 | |
| 64406-024 | Tofidence | TOCILIZUMAB | Biogen MA Inc. | INJECTION | 2024-05-01 | |
| 65219-590 | TYENNE | Tocilizumab-aazg | Fresenius Kabi USA, LLC | INJECTION, SOLUTION, CONCENTRATE | 2024-04-15 | |
| 65219-592 | TYENNE | Tocilizumab-aazg | Fresenius Kabi USA, LLC | INJECTION, SOLUTION, CONCENTRATE | 2024-04-15 | |
| 65219-594 | TYENNE | Tocilizumab-aazg | Fresenius Kabi USA, LLC | INJECTION, SOLUTION, CONCENTRATE | 2024-04-15 | |
| 72606-042 | AVTOZMA | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION | 2025-01-26 | |
| 72606-043 | AVTOZMA | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION | 2025-01-26 | |
| 72606-044 | AVTOZMA | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION | 2025-01-26 | |
| 72606-045 | AVTOZMA | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION | 2025-01-26 | |
| 72606-048 | Tocilizumab-anoh | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2025-01-26 | |
| 72606-049 | Tocilizumab-anoh | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2025-01-26 | |
| 72606-050 | Tocilizumab-anoh | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2025-01-26 | |
| 72606-051 | Tocilizumab-anoh | tocilizumab | CELLTRION USA, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2025-01-26 | |
| 78206-200 | TOFIDENCE | TOCILIZUMAB | Organon LLC | INJECTION | 2025-07-03 | |
| 78206-201 | TOFIDENCE | TOCILIZUMAB | Organon LLC | INJECTION | 2025-07-03 | |
| 78206-202 | TOFIDENCE | TOCILIZUMAB | Organon LLC | INJECTION | 2025-07-03 |
Loading full table content...